Mylan in $17.5M deal with Pfizer for generic asthma, COPD products
This article was originally published in Scrip
Executive Summary
US generic drug maker Mylan is paying Pfizer $17.5 million for the exclusive worldwide rights to develop, manufacture and commercialize its generic proprietary dry powder inhaler products that are equivalent to GlaxoSmithKline's Advair Diskus and Seretide Diskus, which are fixed-dose combinations of fluticasone propionate and salmeterol.